Many patients combine B12 with GLP-1/GIP weight loss, weight loss medications, GAC injections, glutathione injections, or NAD+ injections
Retatrutide is an investigational triple receptor agonist that simultaneously targets three key hormonal pathways: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
monoclonal mouse GLP-1 antibody [8G9] (Abcam, Cambridge, UK MA) diluted 1:3000, pH 9, polyclonal Rabbit 5HT (serotonin) antibody (Immunostar WI, USA) diluted 1/10,000, monoclonal mouse/human SST ghrelin antibody (R&D Systems #MAB8200) or anti-SST antibody (Dako, #A0566) both used at a dilution 1:500
Introduction# Ecnoglutide (XW003, Sciwind Biosciences) and semaglutide (Novo Nordisk) are both GLP-1 receptor agonists for obesity and type 2 diabetes, but they differ fundamentally in their signaling pharmacology
Purpose-built for physicians Adults with obesity, preexisting CVD maintain weight loss with semaglutide at 4 years Key takeaways: Of adults receiving semaglutide, 44.2% lost at least 10% of their body weight at 2 years
.png)
